(Q41757247)

8 October 2017

title

Prognostic significance of circulating CD19+ B lymphocytes in EBV-associated nasopharyngeal carcinoma (English)

1 reference

8 October 2017

Tao Xu

1

1 reference

8 October 2017

Zheli Huang

2

1 reference

8 October 2017

Bojin Su

3

1 reference

8 October 2017

Sumei Wang

4

1 reference

8 October 2017

Donghui Wang

5

1 reference

8 October 2017

Chunhua Wang

6

1 reference

8 October 2017

Weihong Wei

7

1 reference

8 October 2017

Jun Jiang

8

1 reference

8 October 2017

Guoyi Zhang

9

1 reference

8 October 2017

Huiling Yang

10

1 reference

8 October 2017

Weihan Hu

11

1 reference

8 October 2017

publication date

3 September 2014

1 reference

8 October 2017

1 reference

8 October 2017

volume

31

1 reference

8 October 2017

issue

10

1 reference

8 October 2017

page(s)

198

1 reference

8 October 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

The battle against nasopharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Treatment for metastatic nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Increase in circulating Foxp3+CD4+CD25(high) regulatory T cells in nasopharyngeal carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Pretreatment Epstein-Barr virus DNA load and cumulative cisplatin dose intensity affect long-term outcome of nasopharyngeal carcinoma treated with concurrent chemotherapy: experience of an institute in an endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Epstein-Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Importance of CD4(+) T helper cell responses in tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

CD4 T cells in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

CD4 lymphopenia to identify end-of-life metastatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Multiparametric bioinformatics distinguish the CD4/CD8 ratio as a suitable laboratory predictor of combined T cell pathogenesis in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Cancer stem-like cell characteristics induced by EB virus-encoded LMP1 contribute to radioresistance in nasopharyngeal carcinoma by suppressing the p53-mediated apoptosis pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0198-Y

21 January 2018

Nasopharyngeal carcinoma

1 reference

12 December 2020

Unfavorable clinical implications of circulating CD44+ lymphocytes in patients with nasopharyngeal carcinoma undergoing radiochemotherapy

1 reference

12 December 2020

Concurrent weekly docetaxel chemotherapy in combination with radiotherapy for stage III and IVA-B nasopharyngeal carcinoma

1 reference

12 December 2020

Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex

1 reference

12 December 2020

10.1007/S12032-014-0198-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

8 October 2017

1024410556

0 references

1 reference